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Elicitation of broadly cross-reactive neutralizing antibodies (bcnAbs) in HIV infections is rare. To test the hypothesis that such antibodies could
be elicited by HIV envelope glycoproteins (Envs) with unusual immunogenic properties and to identify novel bcnAbs, we used a soluble Env
ectodomain (gp140) from a donor (R2) with high level of bcnAbs as an antigen for panning of an immune phage-displayed antibody library. The
panning with the R2 Env resulted in significantly higher number of cross-reactive antibody clones than by using Envs from two other isolates
(89.6 and IIIB). Two of the identified human monoclonal antibodies (hmAbs), m22 and m24, had sequences, neutralizing and binding activities
similar or identical to those of the gp120-specific bcnAbs m18 and m14. The use of the R2 Env but not other Envs for panning resulted in the
identification of a novel gp41-specific hmAb, m46. For several of the tested HIV-1 primary isolates its potency on molar basis was comparable to
that of T20. It inhibited entry of primary isolates from different clades with an increased activity for cell lines with low CCR5 surface
concentrations. The m46 neutralizing activity against a panel of clade C isolates was significantly higher in an assay based on peripheral blood
mononuclear cells (4 out of 5 isolates were neutralized with an IC50 in the range from 1.5 to 25 μg/ml) than in an assay based on a cell line with
relatively high concentration of cell-surface-associated CCR5. In contrast to 2F5 and Z13, this antibody did not bind to denatured gp140 and
gp41-derived peptides indicating a conformational nature of its epitope. It bound to a 5-helix bundle but not to N-heptad repeat coiled coils and a
6-helix bundle construct indicating contribution of both gp41 heptad repeats to its epitope and to a possible mechanism of neutralization. These
results indicate that the R2 Env may contain unique exposed conserved epitopes that could contribute to its ability to elicit broadly cross-reactive
antibodies in animals and humans; the newly identified antibodies may help in the development of novel vaccine immunogens and therapeutics.
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Elicitation of broadly cross-reactive HIV-1 neutralizing
antibodies (bcnAbs) in vivo is rare (Burton and Montefiori,
1997) likely due to protection of conserved structures of the
virus envelope glycoprotein (Env) by variable loops, extensive
glycosylation, occlusion within the oligomer, and conforma-
tional masking, and the rapid generation of mutants that outpace
the development of such antibodies (Poignard et al., 2001;
Johnson and Desrosiers, 2002; Burton, 2002; Wei et al., 2003;
Richman et al., 2003; Garber et al., 2004). A number of Env-
specific hmAbs have been identified (Zolla-Pazner, 2004) but
only several exhibited neutralizing activity to primary isolates
from different clades (Ferrantelli and Ruprecht, 2002; Burton,
2002) including IgG b12 (Roben et al., 1994; Burton et al.,
1994), IgG 2G12 (Trkola et al., 1996; Scanlan et al., 2002;
Sanders et al., 2002), m14 (Zhang et al., 2004), m18 (Zhang et
al., 2003), 447-52D (Gorny et al., 1992), IgG 2F5 (Muster et al.,
1993), IgG 4E10 (Stiegler et al., 2001; Zwick et al., 2001), Fab
X5 (Moulard et al., 2002) and Fab Z13 (Zwick et al., 2001).
Identification and characterization of novel bcnAbs may
provide additional insights into the closely guarded conserved
structures that could serve as epitopes for neutralizing anti-
bodies, as well as for understanding mechanisms of HIV entry
and evasion of immune responses, and for development of
vaccines or entry inhibitors.
Recently, it has been proposed that individuals possessing
bcnAbs were infected with viruses encoding Envs with unusual
immunogenic properties (Cham et al., 2006). We have
hypothesized that mimicking immune responses by using
such Envs as selecting antigens for screening of immune
human antibody libraries could not only further test this
proposition but also may lead to identification of novel bcnAbs
with implications for development of vaccine immunogens,
inhibitors and research tools.
The clade B, R2 Env was isolated from a donor (R2) with
long-term nonprogressive HIV-1 infection and high level of
bcnAbs (Vujcic and Quinnan, 1995; Quinnan et al., 1999;
Zhang et al., 2002). It has been shown to mediate CD4-
independent HIV-1 entry into cells and utilizes CCR5 but not
CXCR4 as coreceptor. Immunization of small animals and
macaques with the R2 Env resulted in induction of antibodies
that neutralized heterologous primary HIV-1 strains (Dong et
al., 2003; Quinnan et al., 2005). Here we describe the selection
of bcnAbs by using an antigen based on the recombinant
soluble form of the Env ectodomain (gp140R2). The antibodies
selected from an immune human Fab phage display library by
panning against gp140R2 bound to Envs from primary isolates
and inhibited entry mediated by Envs of primary isolates from
different clades. One unique gp41-specific bcnAb, m46, was
identified which in contrast to 2F5, 4E10 and Z13 binds to a
conformational epitope. These results indicate that as pre-
viously proposed, the Env from the R2 isolate may have unique
exposed conserved epitopes targeted by broadly cross-reactive
antibodies that may have potential as vaccine immunogens and
as targets for inhibitors. The selected antibodies can be used for
identification and characterization of these conserved epitopesthat can serve as templates for design of new vaccine
immunogens (a retrovaccinology approach for development of
vaccines). These antibodies could also have potential as
therapeutics in combination with other antiretroviral drugs
including other antibodies, and as research reagents.
Results
Selection of phage-displayed Fabs by panning against gp140R2
and control gp140s
The R2 Env gene was isolated from a donor (R2) with long-
term nonprogressive HIV-1 infection whose serum contains
broadly cross-reactive primary isolate neutralizing antibodies
(bcnAbs) and the R2 Env can be neutralized cross-reactively by
HIV-immune human sera; the R2 Env is competent for CD4-
independent infection and a soluble oligomeric form (gp140R2)
elicited bcnAbs in monkeys indicating enhanced exposure of
conserved epitopes (Quinnan et al., 1999, 2005; Zhang et al.,
2002). Therefore, we have hypothesized that panning of phage-
displayed antibody libraries against (gp140R2) is likely to result
in selection of bcnAbs. To test this hypothesis, and to begin to
identify and characterize conserved epitopes on R2, we used
gp140R2 as an antigen for panning of an immune human
antibody library derived from three long-term nonprogressors
with high level of bcnAbs. Two strategies were used: (1)
standard biopanning where gp140 alone was incubated with the
library and (2) a procedure, we recently developed (Zhang et al.,
2006), termed competitive antigen panning (CAP), where
tagged gp140 is mixed with an excess of untagged gp120 and
the library; thus the CAP methodology enhances selection of
gp41-specific antibodies in the context of gp140.
With the first strategy four rounds of panning were
performed using gp140R2 as selecting antigen. The resulting
libraries were screened with gp140R2, gp12089.6, gp120JR-FL
and gp140IIIB. Total of 30 clones from the third and fourth
rounds were screened by phage ELISA and 14 highest affinity
binders were sequenced. Table 1 shows the sequences of the
heavy chain complementarity determining region 3 (H3) of
selected antibody clones and their similarity to known hmAbs.
Three clones had almost identical sequences between them-
selves and with m18, which was selected by SAP using
gp14089.6 and gp140IIIB (Zhang et al., 2003, 2006). One of these
clones was identical to m18 and designated as m22—we wish to
keep this designation to indicate that it was selected by using
R2. Five clones were also similar to m18 (differed by two
residues in the heavy chain), while one clone had the same
heavy chain as m18 but different light chain. Two clones were
similar to m14, which was also selected by using SAP with
gp14089.6 and gp140IIIB as selecting antigens (Zhang et al.,
2004). One of these clones, designated as m24, differed from
m14 by one residue in the CDRH3 and three other residues in
the framework. Fabs m22 and m24 were expressed, purified and
tested for neutralization.
To find out whether other Envs used as antigens can also lead
to selection of cross-reactive antibodies including antibodies
similar to m14 and m18, we performed four rounds of panning
Table 1
Sequences of the H3s of antibody clones selected by panning against gp140R2
The antibody DNA was sequenced and the amino acid sequences of the
complementarity determining region 3 (H3) were determined by using the GCG
program. The differences of each clone are highlighted in comparison to the
previously identified antibodies m14 and m18.
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(gp14089.6) and IIIB (gp120IIIB) using the same panning
conditions as for gp140R2, and screened 30 antibody clones
selected by each panning antigen with gp140R2, gp120IIIB and
gp14089.6 using phage ELISA. Most of the clones (94%)
selected by using gp140 from R2 bound to the homologous
selecting antigen (gp140R2) but also significant number (about
30–40%) bound to the heterologous Envs IIIB and 89.6 (Fig. 1).
Using Env glycoproteins from 89.6 and IIIB isolates as
selecting antigens also lead to high number of clones that
bound to their respective homologous antigens although that
number (about 60% of all selected clones) was smaller than the
respective percentage for R2 (94%); interestingly, in both casesFig. 1. Monoclonal phage ELISA reactivity of antibody clones. Screening
antigens (gp140R2, gp14089.6, gp140IIIB) were captured by the polyclonal sheep
anti-gp120 antibody D7324 (5 μg/ml) coated on 96-well plates. Phage
supernatants of 30 clones from each panning experiment were added, bound
phage was detected by anti-M13-HRP antibody and optical density was
measured at 450 nm. The number of antibody clones that bind to the screening
antigen is shown as percentage of the total number of clones (30).about the same number of clones (about 60%) bound also to the
heterologous Env (gp140 from R2) (Fig. 1). However, fewer
clones (about 10%) selected by using Env glycoproteins either
from IIIB or 89.6 cross-reacted with each other (Fig. 1). The
highest binders in phage ELISAwere sequenced and compared
to the m14 and m18 sequences. Two independent panning
experiments with gp140R2 resulted in maximum number of
antibody clones similar to either m14 or m18 (73% of
sequenced clones), while significantly smaller number of clones
from panning with gp120IIIB (33%) and gp14089.6 (10%) were
similar to these two cross-reactive antibodies (Table 2). These
results suggest that gp140 from R2 contains conserved
structures that serve as epitopes of bcnAbs like m14 and m18,
and that they are more antigenic than those from Envs from IIIB
and 89.6.
With the second strategy (CAP), we selected antibodies that
bind to gp41 by using a mixture of tagged gp140R2 as a
selecting antigen and gp120R2 as a competitor. After the third
and fourth round of panning, 96 antibody clones were screened
by phage ELISA against gp140R2 and gp120R2. One clone,
m46, with the highest binding to gp140R2 and no significant
binding to gp120R2 was selected and sequenced. Its sequence
was unique with a 12-residue long complementarity determin-
ing region 3 (CDR3) of the heavy chain (VIIRGSHYKDDY).
Interestingly, m46 was not selected by using other Envs (89.6,
CM243) as antigens.
These observations indicate that gp140R2 is very antigenic
and contains exposed conserved structures that serve as epitopes
for bcnAbs.
Binding of m22, m24 and m46 to gp120 and gp140 from
different isolates
To further characterize the selected antibodies (m22, m24
and m46) they were expressed as Fabs, purified and their
binding to gp120 and gp140 was measured under various
conditions. M22 and m24 bound to gp140 from 89.6, and gp120
from JR-FL and IIIB with high (nM) affinity and also bound to
several gp140s and gp120s from primary isolates that were not
used in the panning and screening procedures suggesting that
their epitope is exposed in gp120s of isolates from different
clades as measured by an ELISA assay (data not shown). The
kinetics of interaction of m22 and m24 with different Envs was
measured by using an optical biosensor system (Biacore) basedTable 2
Sequence similarity of antibody clones with mAbs m14 and m18
Panning antigen
(number of sequenced clones)
m14 m18
gp140R2 (14) 2 9
gp140R2 (12) 3 5
gp14089.6 (10) – 1
gp120IIIB (12) 1 3
The numbers of clones with sequence similarity to m14 and m18 are shown. The
total numbers of sequenced clones from each panning procedure using gp140R2,
gp120IIIB or gp14089.6 as antigens are in parentheses. The results of two
independent pannings with R2 are shown.
Fig. 2. Competition of m22 and m24 with other CD4bs and CD4i antibodies.
Gp140R2 was captured by the polyclonal sheep anti-gp120 antibody D7324
(5 μg/ml) coated in 96-well plates. Three-fold serially diluted sCD4, Fabs (m14,
m16, m18, X5, m22, m24), and IgGs (b12, 17b) followed by addition of
biotinylatedm22 (A) or m24 (B), at a constant concentration (which leads to 70%
of maximum binding) simultaneously to the wells. Bound antibodies were
detected by streptavidin–HRP and measured as optical densities at 450 nm.
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rate constants for m22 and m24 binding to gp140R2 and
gp14089.6 (tethered) were in a range typical for binding of
antibodies with nM affinity (Table 3). The equilibrium
dissociation constants, derived from the kinetic parameters,
were comparable to the binding affinity observed for m18 and
m14.
To approximately localize the m22 and m24 epitopes we
evaluated the competitive binding activity of Fab m22 and Fab
m24 in presence of sCD4 and other anti-gp120 antibodies. M22
and m24 competed significantly with sCD4 and IgG b12, and
two other CD4bs antibodies (m14 and m18) but only weakly
with IgG 17b and another CD4i antibody Fab X5 (Fig. 2). These
results further suggest that m22 and m24 strongly bind to both
gp120 and gp140, and behave as CD4bs antibodies, as observed
earlier with m14 and m18.
To further characterize Fab m46 it was purified and its
binding to gp140s and gp120s from R2 and 89.6 was measured
by ELISA (Fig. 3). We observed high level of binding to the
gp140s but no significant reactivity for the corresponding
gp120s. To determine whether m46 binds to conformational
epitopes, we prepared denatured gp14089.6 (tethered), by adding a
reducing reagent. Unlike binding to native gp140, binding of
m46 to denatured gp140 was abolished suggesting that m46
recognizes a conformational epitope on gp41 (Figs. 4A and B).
The binding of the other tested gp41 antibodies, IgG 2F5 and
Fab Z13 was not affected by the reducing condition.
To further characterize the binding of m46 to gp41,
competition experiments were performed with different anti-
gp41 antibodies (Fig. 5); the anti-gp120 antibodies IgG b12,
IgG 2G12, and Fab X5 were used as controls for gp41
specificity. We observed competition with two recently
identified gp41 antibodies, Fab m43 and Fab m45 (Zhang et
al., unpublished) and lack of competition with two other gp41
antibodies, IgG 2F5 and IgG 4E10. In contrast to 2F5 and Z13,
m46 strongly competed with the mouse cluster IV antibody T3
(Fig. 6A) but did not compete with the mouse cluster Vantibody
D3 (Fig. 6B). These results indicate that in contrast to the well-
characterized HIV-1 neutralizing anti-gp41 antibodies 2F5,
4E10 and Z13, which can bind linear epitopes, m46 binds to aTable 3
Binding kinetics of m22 and m24 to gp140R2 and gp14089.6 measured by
Biacore
HIV-1 isolate ka (105M−1 s−1) kd (10−4 s−1) KD (nM)
m22 m24 m22 m24 m22 m24
gp140R2
(clade B)
2.1 1.2 1.6 1.5 0.8 1.3
gp14089.6 (tethered)
(clade B)
0.6 0.4 1.6 2.2 2.9 5.2
The experiments were performed as described in the Materials and methods
section — m22 and m24 were injected (30 μl/min) at different concentrations
(50, 25, 12.5, 6.25 and 3.125 nM) over a CM5 sensor chip, containing captured
gp140R2 and gp14089.6 (tethered). The association, ka, and dissociation, kd, rate
constants were calculated by fitting both association and dissociation phases
with a 1:1 Langmuir global model using BIAevaluation 4.1 software, and the
equilibrium dissociation constant, KD, was determined from their ratio.conformational epitope on gp41 that is likely localized in a
region different than the epitopes of 2F5, 4E10 and Z13.
To further characterize the epitope of m46, we measured by
ELISA m46 binding to thirty-four peptides derived from
different regions of gp41, including six peptides from the
membrane-proximal external region (MPER) where 2F5, 4E10
and Z13 bind. We did not observe any significant binding of
m46 to the tested peptides including DP178 (T20), C34, N36
and the peptide 2031 (Fig. 7 and data not shown). These results
were further confirmed by competition ELISA with T20 (Fig.
8), where T20 competed with IgG 2F5 but did not compete with
IgG m46 and Fab Z13. These observations further indicate that
m46 recognizes a conformational epitope that is different from
the epitopes of other known anti-gp41 antibodies such as 2F5,
Z13 and 4E10.
In an attempt to localize the m46 epitope we measured its
binding to five soluble trimeric polypeptides derived from gp41:
Fig. 4. Binding of m46 to native (A) and denatured tethered gp14089.6 (B).
Tethered gp14089.6 or denatured gp14089.6 at 1 μg/ml (prepared as described in
Materials and methods) was coated on 96-well plates. The plates were blocked
using 3% BSA in PBS, and 3-fold serially diluted anti-gp41 antibodies with
starting concentration of 10 μg/ml were added to the wells. Bound antibodies
were detected using HRP-conjugated anti-human IgG, F(ab′)2 and ABTS as
substrate. Optical density at 405 nm was measured.
Fig. 3. Binding of m46 to gp140/120 from primary isolates. Gp140/gp120s were
coated on 96-well plates, washed and m46 was added at the indicated
concentrations. Bound antibodies were detected by anti-human IgG F(ab′)2-
HRP and measured as optical densities. The background, determined as the
amount of Fab bound to BSA, was subtracted. Standard variation of triplicate
wells was on average around 5%.
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ectodomain core of gp41 – the 6-helix bundle (6-HB) (Louis et
al., 2005) and a single chain 5-helix bundle (5-HB), which folds
into a structure similar to the trimers-of hairpins, but with an
unoccupied binding site for a C peptide (Root et al., 2001). Fab
m46 bound weakly only to the 5-HB (Fig. 9 and data not
shown) indicating that its conformational epitope includes
structures from both (N and C) heptad repeats.
Neutralizing activity of m46 against primary HIV-1 isolates
from different clades
The neutralizing activity of Fab m46 to primary isolates from
different clades was tested by using assays based on cell lines
infected by pseudovirus and on PBMCs infected by replication-
competent virus. For a panel of clade C isolates, which are not
neutralized by 2F5, m46 was much more potent in the PBMC-
based assay than in the cell line/pseudovirus-based assay (Table
4). To account for possible differences between pseudovirus and
virus derived from PBMCs, m46 was also tested in the same cell
line (TZM-bl) but with a PBMC-derived virus. The results
indicate that the use of PBMCs as target cells but not the nature
of the virus containing the same Env is a major determinant of
the high neutralizing activity of m46 (Table 4). PBMCs have
lower CCR5 concentration in comparison to cell lines used in
neutralization assays (Choudhry et al., 2006). Experiments with
HeLa cell lines expressing high or low levels of CCR5 were
performed to evaluate the effect of the CCR5 concentration on
the neutralizing activity of m46 and other gp41 antibodies. For
the cell line with low CCR5 cell surface concentration we
observed a significant increase in the neutralizing activity of
both Fab and IgG m46, and of two other gp41 antibodies, 2F5
and 4E10, against different primary isolates of HIV-1 (Table 5).In a separate set of experiments we compared the neutralizing
activity of IgG m46 with the potent inhibitor of HIV-1 entry, the
gp41-derived peptide T20 which is the only entry inhibitor
currently in clinical use (Table 6). On amolar basis the inhibitory
activity of m46 was on average approximately comparable to
that of T20–for two isolates (from clades A and C) the activity of
the two inhibitors was comparable, for two other isolates (from
clades B and E) the IC50 for T20 was several fold lower than that
for IgG m46 and for one isolate (from clade D) IgG m46 was
much better inhibitor than T20. The inhibitory activities of IgG
m46 and T20 were also compared in a PBMC based assay for
an isolate from clade B (92BR020) (Fig. 10). Not only the
IC50s for IgG m46 and T20 were comparable (173± 26 nM and
154±17 nM, respectively) but also the functional dependences
of the virus concentration on the inhibitor concentration were
similar. These results suggest that m46 is a cross-reactive HIV-
1-neutralizing antibody which exhibits neutralizing potency for
Fig. 5. Competition of m46 with anti-gp41, CD4bs and CD4i antibodies.
Gp140R2 was captured by the polyclonal sheep anti-gp120 antibody D7324
(5 μg/ml) coated on 96-well plates. Serially diluted sCD4, different Fabs (X5,
m43, m45) and IgGs (b12, 2F5, 4E10, 2G12) were added, along with
biotinylated m46 at a constant concentration that led to 70% of maximum
binding, simultaneously to the wells. Bound antibodies were detected by
streptavidin–HRP and measured as optical densities at 405 nm.
Fig. 6. Competition of m46 with anti-gp41 antibodies. 1 mg/ml gp14089.6 was
coated on 96-well plates. Two-fold serially diluted IgG m46, IgG 2F5 and Fab
Z13 were added to the wells and biotinylated mouse monoclonal antibody
(mAb) T3 and D3 at a constant concentration corresponding to 70% maximum
binding was simultaneously added to the wells. Bound biotinylated T3 (A) and
D3 (B) were detected using streptavidin–HRP at 450 nm.
84 V. Choudhry et al. / Virology 363 (2007) 79–90the tested isolates approximately comparable to that of T20 on a
molar basis with a mechanism dependent on the CCR5
concentration.
Discussion
The major findings of this study are the demonstration of
high level of exposed conserved epitopes on the R2 Env and the
identification of novel bcnAbs. The finding that the use of an
Env (R2) isolated from a patient with high level of bcnAbs as an
antigen for panning of an immune human antibody library
resulted in the efficient selection of such bcnAbs further
supports the proposition that donors with broadly cross-reactive
HIV-1 neutralizing sera are likely to be infected with viruses
encoding Envs with unusual immunogenic properties (Cham et
al., 2006). Interestingly, the immune antibody library was
derived not from the R2 donor but from a pool of three other
individuals with high levels of bcnAbs. It is tempting to
speculate that it could be the R2 Env that is capable of eliciting
bcnAbs and not the specific properties of the immune system of
the R2 donor although one might argue that all individuals with
high levels of bcnAbs have such specific properties of their
immune systems leading to enhanced elicitation of bcnAbs. One
can further speculate that R2-like viruses or other viruses with
Envs exposing conserved epitopes caused the elicitation of
bcnAbs in the three donors from which the immune library was
constructed. Whatever the mechanism is, the use of the R2 Env
helped to identify novel bcnAbs; this efficient selection of
bcnAbs indicates its potential as selecting antigen for screening
of antibody libraries and as vaccine immunogen, and provides
novel tools for elucidating mechanisms and developing ofinhibitors and vaccines. Indeed, recently the use of R2 as an
immunogen mixed with an adjuvant elicited antibodies in
rabbits that neutralized all 47 tested primary HIV-1 isolates (G.
Quinnan et al., AIDS Vaccine Meeting, Amsterdam, abstract #
P09A-76).
Of the large number of mAbs and Fabs against Envs until
recently only several human mAbs have been identified that
exhibit broad and potent HIV-1 neutralizing activity (D'Souza
et al., 1997; Binley et al., 2004). The identification of new
broadly cross-reactive HIV-1 neutralizing mAbs suggests that
such antibodies could play even more important role in vivo
than anticipated although we do not have direct evidence that
the antibodies we have identified exist in vivo.
We observed that the R2 Env used as an antigen enables
selection of antibody clones from an immune library, which
cross-react with Envs from the other isolates used in this study
(gp14089.6 and gp120IIIB). However, in phage ELISA antibody
clones selected from panning against gp14089.6 had high cross-
Fig. 7. ELISA reactivity of m46 with selected peptides derived from gp41. Different peptides derived from gp41 were coated at 4 μg/ml concentration on a 96-well
plate. Three-fold serially diluted Fab m46, Fab Z13 and IgG 2F5 were added to the blocked plates. Bound antibodies were detected by addition of HRP-conjugated
anti-human IgG, F(ab′)2 and the absorbance measured by using ABTS substrate.
Fig. 8. Competition of m46 with T20. 1 mg/ml gp14089.6 was coated on 96-well
plates. Two-fold serially diluted T20 was added to the wells and IgG m46, Fab
Z13 or IgG 2F5 was added to the wells at a constant concentration
corresponding to 70% maximum binding. Bound antibodies were detected
using HRP-conjugated anti-human IgG, F(ab′)2 and measuring absorbance at
405 nm.
Fig. 9. Western blot analysis of Fab 46 with soluble gp41 constructs containing
heptad repeats. SDS-PAGE of non-reduced NCCG-gp41 (lane 1), N35CCG-N13
(lane 2), N34CCG (lane 3), 6-HB (lane 4) and 5-HB (lane 5) was electrophoresed
(500 ng/lane) on 20% homogeneous PhastGel and immunoblotted with Fab
m46, and detected by goat anti-human Fab antibody–alkaline phosphatase
conjugate using Fast 5-bromo-4-cloro-3-indolyl phosphate/nitro blue tetrazo-
lium solution. Arrows indicate the molecular mass markers.
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Table 4
Neutralization of HIV-1 primary isolates by the gp41-specific antibody IgG1
m46
Virus PBMC virus/
TZM-bl assay
293T Pseudovirus/
TZM-bl assay
PBMC virus/
PBMC assay
Du123.6 >35 >35 1.5
Du151.2 >35 >35 25
Du156.12 >35 >35 >35
Du172.17 >35 >35 4.5
Du422.1 >35 >35 25
Neutralization assays were performed either using pseudovirus produced in
293T cells or viruses produced in PBMCs and TZM-bl cells or PBMCs as
targets. Shown are IC50s in μg/ml.
Table 6
Comparison of neutralization of HIV-1 primary isolates from different clades by
IgG m46 and T20 measured by a pseudovirus-based assay using cell lines with
different CCR5 surface concentrations
HIV-1 clade Antibody High CCR5 Low CCR5
92UG037.8 (clade A) IgG m46 >334 (41%) 214
T20 445 111
Bal (clade B) IgG m46 247 80
T20 89 8.9
GXC-44 (clade C) IgG m46 >334 (32%) 147
T20 668 89
Z2Z6 (clade D) IgG m46 80 30
T20 734 111
CM243 (clade E) IgG m46 214 67
T20 45 8.9
Various concentrations of IgG m46 and T20 were mixed with viruses
pseudotyped with the Env from different clades of HIV-1 for 30 min at 37 °C
and mixed with cells expressing high or low CCR5 concentrations in triplicate
wells. The IC50 (in nM) was calculated as described in Table 5.
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to gp120IIIB; similarly antibodies obtained by panning against
gp120IIIB had high cross-reactivity to gp140R2 but on average
low level of binding to gp14089.6. These results suggest that the
R2 Env glycoprotein shares common epitopes with the other
Env glycoproteins (gp14089.6 and gp120IIIB) used in panning
but the other Env glycoproteins do not exhibit some of these
common epitopes. Thus the selected antibodies, m22 and m24,
had neutralization activity similar to that of the previously
characterized antibodies m18 (Zhang et al., 2003) and m14
(Zhang et al., 2004). Panning against the other two tested Envs
(89.6 and III B) by using standard panning procedures did not
lead to selection of clones that are broadly cross-reactive orTable 5
Neutralization of HIV-1 primary isolates from different clades by m46, 2F5 and
4E10 measured by a pseudovirus assay using cell lines with different CCR5
surface concentrations
HIV-1 clade Antibody High CCR5 Low CCR5
92UG037.8 (clade A) Fab m46 >50 (40%) 18
IgG m46 >50 (35%) 25
IgG 2F5 0.3 0.2
IgG 4E10 1 0.2
Bal (clade B) Fab m46 45 5
IgG m46 30 8
IgG 2F5 6 1
IgG 4E10 12 0.1
GXC-44 (clade C) Fab m46 >50 (44%) 15
IgG m46 >50 (39 %) 25
IgG 2F5 >25 (20 %) >25 (30%)
IgG 4E10 15 8
Z2Z6 (clade D) Fab m46 20 10
IgG m46 10 3
IgG 2F5 18 9
IgG 4E10 22 10
CM243 (clade E) Fab m46 28 5
IgG m46 25 6
IgG 2F5 3.2 1
IgG 4E10 1.5 0.6
Antibodies at various concentrations were mixed with viruses pseudotyped with
the Env from different clades of HIV-1 for 30 min at 37 °C and mixed with cells
expressing high or low CCR5 concentrations in triplicate wells. The mean
luminescence readings were determined 3 days later and IC50 (μg/ml) was
calculated at the antibody concentration at which 50% neutralization was
observed. The mean of three measured IC50s for each antibody/virus/cell
combination are presented (in μg/ml); the standard deviation was on average 5%
and did not exceed 10%, the numbers in parentheses are the percentages
neutralization measured at those concentrations used (50 or 25 μg/ml).exhibit potent neutralizing activity (data not shown). Interest-
ingly, although the R2 Env can mediate CD4-independent entry,
we were not able to select CD4i antibodies from the panning
against the R2 Env; this could be partially due to the screening
based on gp140s and gp120s in the absence of CD4 and
experiments are in progress to evaluate the possibility for
identification of CD4i antibodies by using R2 Env as an
antigen.
We also selected one gp41-specific antibody (m46) by using
the competitive antigen panning methodology (Zhang et al.,
2006). This antibody binds to a conformational epitope (in
contrast to 2F5 and Z13) and exhibits broad and relatively
potent neutralizing activity. Although currently the exact
localization of its epitope is not known because of lack ofFig. 10. Inhibitory activity of IgG m46 and T20 against an isolate from clade B
(92BR020) measured by a PBMC assay. The PBMCs were activated with
PHA-P for 3 days, infected with HIV-1 in presence of the IgG m46 (open circles
and dashed line) or T20 (solid circles and solid line) for 24 h, washed twice with
PBS and left to grow in RPMI-1640 supplemented with IL-2. Lysis buffer was
added to the cell suspension 3 days later and p24 was detected by standard
capture ELISA. To account for variations in viral replication in the absence of
inhibitors, the Log of p24 was normalized to Log p24 in the absence of
inhibitors. Experimental data were fitted by using the sigmoidal 3-parameter
function of SigmaPlot software (Sysstat Software, Inc., San Jose, CA). IC50s
were calculated from the fitted curves.
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that it does not overlap with the epitopes of 2F5, 4E10 and Z13.
In addition, we found that m46 does not bind to any gp41
peptide tested including N-36, C-34 and T20 (Fig. 7), and it
does not bind to soluble constructs from gp41 containing the
N-terminal heptad repeat and the 6-helix bundle (6-HB) (Fig. 9).
However, it did bind, although weakly, to a construct containing
the 5-HB indicating that its conformational epitope contains
structures from both the N- and C-terminal heptad repeats (Fig.
9). Interestingly, T20, which also binds to the 5-HB, exhibited
similar neutralizing activity on molar basis for several isolates
from different clades (Table 6) and for one isolate tested in a
PBMC-based assay the neutralizing activity as function of the
inhibitor concentration was the same (Fig. 10). It is tempting to
speculate that some of the components of the neutralizing
mechanisms of m46 and T20 are similar and include binding to
fusion intermediates. We also observed that similarly to other
gp41-specific antibodies (2F5, 4E10, Z13) and some CD4-
induced antibodies, the m46 neutralizing activity increased with
a decrease in the cell surface concentration of CCR5. The
concentration of CCR5 on the cell surface has been shown
previously to affect the neutralizing activity of HIV-1-specific
antibodies likely by changing the kinetics of entry (Choudhry et
al., 2006). Further characterization of m46 and its epitope, and
elucidation of its mechanism of inhibition could help in the
development of novel vaccine immunogens and inhibitors.
Overall, these results suggest that the R2 Env exposes
conserved epitopes that could be used as templates for design
of vaccine immunogens and as targets for inhibitors, and that
the new antibodies, especially m46, offer new tools for
development of inhibitors, vaccines and research reagents.
Materials and methods
Cells, viruses, plasmids, soluble CD4 (sCD4), gp120, gp140,
and antibodies
HEK 293T cells were purchased from American Type
Culture Collection (Manassas, VA). HeLa cell lines, expressing
different levels of CCR5, were a gift from D. Kabat
(Department of Biochemistry and Molecular Biology, Oregon
Health and Science University, Portland, Oregon). All cell lines
were maintained in Dulbecco's modified Eagle's medium
(DMEM) with 10% fetal bovine serum. Plasmids used for
expression of various Envs were obtained through the AIDS
Research and Reference Reagent Program (ARRRP), Division
of AIDS, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, from B. Hahn (University of
Alabama at Birmingham), and the remaining clones are
described previously (Vujcic and Quinnan, 1995; Quinnan et
al., 1999; Zhang et al., 2002). The R2 (clade B) Env was from a
patient whose sera demonstrated broad cross-neutralizing
activity previously cloned and has been described elsewhere
(Earl et al., 1994, 2001).
Two-domain soluble CD4 (sCD4) was obtained from the
ARRRP. Thirty-four peptides derived from gp41, including
DP178 (T-20), C34, N36, 2031 were also obtained from theARRRP. Gp12089.6 and gp14089.6 were produced from
recombinant vaccinia viruses, provided by R. Doms (University
of Pennsylvania, PA). Gp120IIIB, and a battery of gp140s
including R2 were also prepared from recombinant vaccinia
viruses and have been extensively detailed elsewhere (Quinnan
et al., 2005). Briefly, recombinant gp140 glycoprotein was
produced by infecting BS-C-1 cells with an appropriate vaccinia
virus encoding the indicated HIV-1 gp140 cassette. The gp140
coding regions have the proteolytic cleavage site between
gp120 and gp41 ectodomain mutated to enhance the yield of
oligomeric glycoprotein. Oligomeric gp140/120 was purified
from serum-free culture supernatants using a combination of
Lentil lectin Sepharose 4B affinity and size exclusion
chromatography. HIV-1 gp140 preparations have been shown
to consist of approximately 40% trimer and 60% dimer (Earl et
al., 1997).
The human mAbs X5, Z13, m9, m14, m16 and m18, and the
mouse mAbs T3 (cluster IV) and D3 (cluster V) (Dreyer et al.,
1999) were produced in our laboratories; b12 was a gift from
D. Burton (The Scripps Research Institute, La Jolla, CA), and
17b was from J. Robinson (Tulane University Medical Center,
New Orleans, LA). The human monoclonal antibodies 2F5 and
4E10 were a gift from H. Katinger (Institute of Applied
Microbiology, University for Agricultural Sciences, Vienna,
Austria). The following antibodies were purchased: polyclonal
sheep anti-gp120 antibody D7324 (Cliniqa, Fallbrook, CA),
HRP-conjugated monoclonal mouse anti-M13 antibody (Phar-
macia, Uppsala, Sweden) and HRP-conjugated polyclonal anti-
human IgG F(ab′)2 antibodies (Jackson ImmunoResearch,
Westgrove, PA).
Antigen panning of phage library and analysis of selected
phage clones
The phage library was constructed using pComb3H
phagemid vector and 30 cm3 of bone marrow obtained from
three long-term nonprogressors (A, H and K) (Montefiori et al.,
1996) whose sera exhibited the broadest (Zhang et al., 2003)
and most potent HIV-1 neutralization (provided by T. Evans,
University of California, Davis, CA). Three immunotubes
(Nunc, Denmark) were coated with 10 μg/ml of gp140R2,
gp120IIIB and gp14089.6 each at 4 °C overnight and blocked
with 3% BSA for 2 h at 37 °C. Phage (5×1012 cfu/ml) were
adsorbed for 2 h at 37 °C and immunotubes were washed 20
times with 1 ml of PBS containing 0.1% Tween-20 and another
20 times with 1 ml of PBS. Bound phage were eluted by
incubation at room temperature (RT) for 10 min with 1 ml of
100 mM triethylamine followed by neutralization with 0.5 ml of
1 M, pH 7.5 Tris–HCl. Eluted phage were rescued by infection
of Escherichia coli TG1 cells and phage library was prepared
for the next round of panning. For each round of panning similar
procedure was used; 30 individual clones after the 3rd and 4th
round of panning were screened by phage ELISA for binding to
Envs of primary isolates of HIV-1. Competitive antigen panning
(CAP) using gp140/120R2 was done by mixing labeled gp140
with 5-fold excess of gp120 (Barbas et al., 2001; Zhang et al.,
2006). Individual clones from each panned library were
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gp140/120R2 by phage ELISA.
Phage ELISA
ELISA was performed by using 96-well Nunc-ImmunoTM
MaxisorpTM surface plates (Nalge Nunc International, Den-
mark) which were coated overnight at 4 °C with 100 μl of Envs
(1 μg/ml in sodium bicarbonate buffer, pH 8.3) blocked in
100 μl of 4% non-fat dry milk in PBS for 1 h at 37 °C. After 4
washes with 0.05% Tween-20/PBS washing buffer, wells were
incubated with 100 μl of phage supernatant for 2 h at 37 °C.
Bound phage were detected by using horse radish peroxidase
(HRP) labeled anti-M13 monoclonal antibody (Amersham
Biosciences, Uppsala, Sweden) with incubation for 1 h at
37 °C and revealed by adding ready-to-use TBS substrate
(Sigma, St. Louis, USA). Color development was performed at
RT for 15 min, quenched by 2 N HCl and monitored at 450 nm.
Preparation of soluble Fabs and binding assays
Phagemid DNA from the selected clones was prepared and
digested with NheI and SpeI to remove gene III fragment, self-
religated and transformed in E. coli XL-1 Blue. Soluble Fabs
were produced and purified using protein G columns as
described (Zhang et al., 2004). ELISA D7324 capture assays
with soluble Fabs (m22, m24 and m46) and recombinant HIV-1
gp120s or gp140s from different isolates were performed by
using 96-well Nunc-ImmunoTM MaxisorpTM surface plates
(Nalgen Nunc International, Denmark) as described (Zhang et
al., 2006). Direct ELISAwas carried out by coating gp120/140s
on the plates at a concentration of 1 μg/ml. In cases using
denatured gp140s, purified gp140s were diluted in 1% sodium
dodecyl sulfate and 50 mM dithiothreitol to 10 μg/ml and boiled
for 5 min, and then diluted 1:10 in PBS and coated on 96-well
plates. Competition ELISA of mAbs (m22, m24 and m46) with
other anti-gp120/gp41 antibodies and sCD4 were carried out
using D7324 capture assay as following: 1 μg/ml gp140R2 was
captured by the polyclonal sheep anti-gp120 antibody D7324
(5 μg/ml) coated on 96-well plates. Following the addition of 3-
fold serially diluted Fabs (m14, m16, m18, X5), IgGs (b12, 17b)
and sCD4, equal volume of biotinylated Fabs (m22, m24 and
m46) at a concentration, which led to 70% maximum binding,
was simultaneously added to each well. Bound biotinylated
Fabs were detected by streptavidin–HRP (Pierce, Rockford, IL)
and optical densities were measured. In another set of
experiments, 1 mg/ml gp14089.6 was coated on 96-well plates.
Two-fold serially diluted m46, 2F5 and Z13 were added to the
wells and biotinylated mouse monoclonal antibody T3 and D3
at a constant concentration corresponding to 70% maximum
binding was simultaneously added to the wells. Bound
biotinylated T3 and D3 were detected using HRP conjugated
to streptavidin and ABTS substrate and measured the
absorbance at 405 nm.
The kinetics of m22 and m24 binding was measured by
Biacore 1000 optical instrument (Biacore, Pharmacia, Piscat-
away, NJ). An anti-gp41 human monoclonal antibody Fab(m43) developed recently in our laboratory (Zhang et al., 2006)
was immobilized on a (CM5) sensor chip using carbodiimide
coupling chemistry. Gp140 (200 nM) was injected at a flow rate
of 10 μl/min and varying concentrations of antibodies (Fabs)
were then injected at a flow rate of 30 μl/min using PBS buffer
(pH 7.4) with 0.05% Tween-20. Control surface was prepared
similarly and the experiments were performed by injecting
solutions containing different concentrations of antibodies
using running buffer in lieu of gp140s. All the sensograms
were corrected by subtracting the low signal from the control
reference surface. The association and dissociation phase data
were fitted simultaneously to a 1:1 Langumir global model by
using the nonlinear data analysis program BIAevaluation 4.1.
Binding of Fab m46 to soluble trimeric coiled-coil constructs
from gp41 was performed by Western blot analysis as
previously described (Louis et al., 2005).
HIV-1 Env clones and pseudovirus preparation
Viruses pseudotyped with Envs from HIV-1 primary isolates
representing HIV-1 group M, clades A–F (Zhang et al., 2003),
and laboratory adapted HIV-1 isolates and JRCSF were used in
this study. Cloning of HIV-1 envelope genes and preparation of
pseudoviruses have been previously described (Zhang et al.,
2003). Briefly, pseudotyped viruses were prepared by cotrans-
fection of 70% to 80% confluent HEK 293T cells with pNL4-3.
luc.E-R- and HIV-1 Env plasmid using the calcium phosphate/
HEPES buffer, according to manufacturer's instruction (Pro-
mega, Madison, WI). Eighteen hours after the transfection,
medium was replaced with medium supplemented with 0.1 mM
sodium butyrate (Sigma, St. Louis, USA). Cells were allowed to
grow for an additional 24 h. The supernatant was harvested,
centrifuged at 16,000 rpm for 5 min at 4 °C, filtered through a
0.45-μm pore filter (Millipore, Bedford, MA), prior to use in
neutralization assays.
HIV-1 neutralization assays
Single-round infectious molecular clones, produced by
envelope complementation as described above, were used.
The degree of virus neutralization by antibody was achieved by
measuring luciferase activity as described previously (Platt et
al., 1998). Briefly, neutralization assays were carried out in
triplicate by preincubation of 25 μl of 2-fold serial dilution of
mAbs with 25 μl of pseudovirus suspension for 1 h at 4 °C.
Virus–antibody mixtures were then combined with 150 μl
suspensions of 1–2×104 HOS CD4+ CCR5+/CXCR4+, in 96
wells of tissue culture plates (Costar, Corning, NY). Similar
experiments were done with HeLa cells expressing different
concentrations of CCR5, high CCR5 (clone JC.53) or low
CCR5 (clone JC.10) (Choudhry et al., 2006). Plates were
incubated at 37 °C in 5% CO2 for 3 days and then washed with
PBS and lysed for 30 min with 15 μl of 1 × Luciferase Assay
System cell lysis buffer (Promega, Madison, WI), and
luminescence readings for triplicate wells were determined by
lumiCount microplate luminometer (Turner Designs). Neutra-
lization titers were determined based on relative luminescence
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tion of mAbs at which mean results from the test samples were
less than 50% of non-neutralized control mean. IC50 of
neutralization was assigned for the antibody concentration at
which 50% neutralization was observed. Neutralization assays
for each Env were generally repeated in at least two independent
experiments
Testing of m46 with a panel of clade C isolates (CCR5
phenotype), was also performed by a pseudovirus assay
(designated here as TZM-bl assay), which is similar to the
assay described above, but TZM-bl cells were used as targets for
infection (Li et al., 2005). The clade C, Du gp160 clones used in
TZM-bl assay were derived from acute/early sexually acquired
infections in South Africa (Bures et al., 2000). The same panel
of clade C and other primary isolates were also tested by using
an assay based on inhibition of HIV-1 infection in PBMCs by
measuring p24 (Bures et al., 2002).
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